TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24417987
Drug: aranidipine 20
Normalized name: lercanidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aranidipine 20 mg/d
Study: 19487960
Drug: Single-agent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent therapy (gemcitabine or vinorelbine)
Study: 15142327
Drug: Lower dosage
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dosage group (9 daily sessions)
Study: 9486672
Drug: Flurandrenolide tape
Normalized name: Flurandrenolide Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurandrenolide tape (4 microg/cm2) applied once daily for up to 16 hours
Study: 9486672
Drug: Diflorasone diacetate
Normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflorasone diacetate ointment (0.05%) applied twice daily
Study: 16298650
Drug: No antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibody induction (Control)
Study: 2974715
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cilazapril and propranolol
Study: 2974715
Drug: Cilazapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (2.5 mg day‐1)
Study: 2974715
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg day‐1)
Study: 26073770
Drug: Web-assisted calprotectin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-assisted calprotectin-based treatment algorithm (IBD-live)
Study: 16607097
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg/day
Study: 15162251
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement of 47 mg per day
Study: 15162251
Drug: Dietary plan
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dietary plan rich in iron providing 26 mg per day
Study: 10931747
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of rhGH (5, 10 or 15 mg per 1.5 ml)
Study: 8340985
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic cream, eutectic mixture of local anesthetics (EMLA)
Study: 26812786
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (tapered over 14 days)
Study: 26812786
Drug: Intratympanic methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic methylprednisolone (40 mg/mL, injected twice a week for 2 weeks)
Study: 24988909
Drug: Placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges (n=97)
Study: 18822733
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate hydrogel (1 mL/cm2)
Study: 16236845
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice daily for 10 days
Study: 7757984
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy (cisplatin 80 mg/m2 i.v. on day 1, vindesine 3 mg/m2 i.v. on days 1 and 8, with or without mitomycin 8 mg/m2 i.v. on day 1)
Study: 7216093
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release iron preparations
Study: 7216093
Drug: Quick release
Normalized name: Zinc 50 mg + Vitamin C Quick Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quick release iron preparations
Study: 7216093
Drug: All oral
Normalized name: Exall Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: All oral iron preparations
Study: 23635552
Drug: Sunitinib 25
Normalized name: sunitinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 25 mg orally daily and rapamycin 2 mg orally daily (4 weeks on, 2 weeks off)
Study: 15990827
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (NAC) at a loading dose of 70 mg/kg 2 hours before and 35 mg/kg at 4-hour intervals for a total of 24 hours after the procedure
Study: 31421008
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (NAC)
Study: 8884623
Drug: Intravenous indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous indomethacin 50 mg
Study: 1868973
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole, administered intravenously 4 times a day
Study: 6354530
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg) + Naloxone (0.2 mg/kg i.v.)
Study: 29071072
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal therapy (HFNT)
Study: 26802156
Drug: Cediranib 45
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 45 mg once daily and placebo (C)
Study: 22334456
Drug: sorafenib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib at a dose of 400 mg twice daily
Study: 19103363
Drug: Low- to
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low- to mid-potency topical steroids (short-term therapy for 2-4 weeks)
Study: 19103363
Drug: Topical calcipotriene
Normalized name: calcipotriene Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriene (calcipotriol), pimecrolimus, or tacrolimus (long-term therapy)
Study: 9798024
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg twice a day for 14 days)
Study: 9798025
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg twice a day for 14 days)
Study: 7697951
Drug: MK-0591 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0591 (250 mg)
Study: 2507831
Drug: Special precautions
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special precautions (topical lidocaine by inhalation, bronchoscope through endotracheal tube)
Study: 322635
Drug: Ethanol (1.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (1.32 ml/kg of body weight)
Study: 16430312
Drug: Repeated dosing
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dosing of ximelagatran 48mg every 12 hours for 5 days
Study: 16430312
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ximelagatran 48mg on day 6
Study: 16430312
Drug: Repeated dosing
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dosing of ximelagatran
Study: 14667010
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no fissure sealant, received oral health education)
Study: 10945014
Drug: Vinorelbine (monotherapy)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (monotherapy)
Study: 19940281
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen treatment
Study: 1582503
Drug: AR content
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR content (greater than or equal to 10 pmol/g)
Study: 27872111
Drug: Ultrasound tailored
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound tailored treatment (disclosure of the ultrasound diagnosis)
Study: 22221670
Drug: Improvisational music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improvisational music therapy (one session per week)
Study: 22221670
Drug: Improvisational music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improvisational music therapy (three sessions per week)
Study: 19781847
Drug: Vardenafil 5
Normalized name: vardenafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 5 mg/d at bedtime
Study: 9141524
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cetrorelix for 5 days followed by 2 x 1 mg/day
Study: 9141524
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cetrorelix for 5 days followed by 1 mg/day
Study: 9141524
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections for 3 weeks
Study: 8246770
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g galactose + 25 g glucose
Study: 3658567
Drug: Standard methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard methylphenidate (Ritalin, 10 mg, administered twice daily)
Study: 18345471
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of specific psychotherapies with antidepressive medication
Study: 14524397
Drug: Nonpharmacologic methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic methods of pain relief (labor support, intradermal water blocks, warm water baths)
Study: 25031330
Drug: Maternal urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal urinary iodine concentration (UIC) < 1.0 mg/L
Study: 9256128
Drug: Amifostine (740
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (740 or 910 mg/m2) followed by cisplatin (120 mg/m2) and vinblastine (5 mg/m2)
Study: 9256128
Drug: Amifostine (340
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (340 mg/m2 4 days a week for 5 weeks, or 200 mg/m2 5 days a week for 6 weeks) before radiation therapy
Study: 1723460
Drug: Enalapril (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20‐40 mg daily)
Study: 7470225
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg IV)
Study: 24354263
Drug: travoprost-timolol fixed
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: travoprost-timolol fixed combination (both groups)
Study: 17460095
Drug: 2 MENT
Normalized name: MENT
DrugBank: Trestolone (DB05830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 MENT implants
Study: 17460095
Drug: 600-mg testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600-mg testosterone pellets every 12 weeks
Study: 8623729
Drug: tissue-plasminogen activator
Approvals — FDA: no, EMA: no, PMDA: no
Description: tissue-plasminogen activator (t-PA) plus weight-adjusted heparin
Study: 8623729
Drug: anisoylated plasminogen
Normalized name: Anisoylated plasminogen streptokinase activator complex
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anisoylated plasminogen streptokinase activator complex (APSAC) without heparin
Study: 8623729
Drug: low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-dose aspirin (81 mg)
Study: 8623729
Drug: standard-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard-dose aspirin (325 mg)
Study: 24048581
Drug: Goal-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed fluid therapy (GDT)
Study: 18037095
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg/d for 6 weeks
Study: 12383565
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg Hu23F2G (LeukoArrest)
Study: 30992081
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (30 mg elemental zinc)
Study: 28402324
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 supplementation (50 μg daily during pregnancy through 6 weeks postpartum)
Study: 25910787
Drug: Visualization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visualization of coronary artery calcification and lifestyle recommendations (subgroup with statin therapy)
Study: 22683672
Drug: Diphtheria-tetanus-pertussis vaccine
Normalized name: DIPHTHERIA/TETANUS/PERTUSSIS VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus-pertussis vaccine (DTP) administered after measles vaccine
Study: 15342614
Drug: Quinidine (Q)
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine (Q) 0, 2.5, 10, 25, 50, or 75 mg twice daily with 30 mg Dextromethorphan (DM) for 7 days
Study: 8042612
Drug: Placebo coadministered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo coadministered with chemotherapy
Study: 8042612
Drug: rhGM-CSF (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM-CSF (5.5 micrograms/kg SC) coadministered with chemotherapy
Study: 25465680
Drug: Granisetron transdermal
Normalized name: Granisetron Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron transdermal system (GTS), one patch on days 1-4
Study: 25465680
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral granisetron (control), intravenous on day 1 and oral on days 2-4
Study: 25465680
Drug: Granisetron transdermal
Normalized name: Granisetron Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron transdermal system (GTS) and control
Study: 23535223
Drug: Azelnidipine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine (16 mg/day)
Study: 23535223
Drug: Thiazide diuretic
Normalized name: Thiazide diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic (trichlormethiazide 1 mg/day)
Study: 15730349
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (200 mg/day) and L-carnitine (500 mg/day) combination
Study: 10407842
Drug: Methadone substitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone substitution therapy
Study: 2344089
Drug: 1% povidone‐iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% povidone‐iodine solution (PI)
Study: 7027925
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of trimethoprim (TMP) per day for 14 days
Study: 7027925
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g of sulfisoxazole (SZ) per day for 14 days
Study: 7027925
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of trimethoprim (TMP) per day for 10 days
Study: 16388213
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.1% bupivacaine 10 ml/hour
Study: 16388213
Drug: Intermittent injection
Normalized name: Jelco Intermittent Injection Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent injection of 0.1% bupivacaine 10 ml hourly
Study: 24328607
Drug: Er,Cr:YSGG laser-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er,Cr:YSGG laser-assisted treatment with radial firing tips (RFT2 and RFT3)
Study: 22909165
Drug: 20, 40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20, 40, 80, or 120 μg of total grass pollen recombinant protein
Study: 16275822
Drug: High-dose oxcarbazepine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxcarbazepine (60 mg/kg/day)
Study: 2265051
Drug: suxamethonium 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 2 mg kg‐1 in children
Study: 2265051
Drug: suxamethonium 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 2 mg kg‐1 in infants
Study: 2265051
Drug: suxamethonium 3-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 3-4 mg kg‐1 in infants
Study: 31795546
Drug: D-galactose aging
Normalized name: D(+)-Galactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-galactose aging model group, subcutaneous injection of D-galactose (500 mg/kg) daily for 6 weeks
Study: 31795546
Drug: Blank control
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank control group, no treatment performed
Study: 22801471
Drug: Sensory cueing,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensory cueing, non‐activated wristwatch device and 5 hours of conventional therapy per week (treatment A)
Study: 22801471
Drug: Activated wristwatch
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated wristwatch prompting predetermined exercises on the hemiplegic arm for 6 hours daily, 5 days per week for three weeks (treatment B)
Study: 18095278
Drug: Exogenous melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous melatonin administered at 22:00 h
Study: 1355640
Drug: Inhaled beta‐2‐agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta‐2‐agonist (salbutamol 0.2 mg) plus placebo three times a day (BA+PL)
Study: 27414470
Drug: Trauma-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive behavioral therapy (TF-CBT) delivered by lay counselors
Study: 26331348
Drug: Plerixafor (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (240 mg/kg subcutaneously) in combination with G-CSF (5 mg/kg/day increasing to 10 mg/kg/day)
Study: 26331348
Drug: Plerixafor (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (240 mg/kg)
Study: 19597422
Drug: Plerixafor and
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor and G-CSF
Study: 19380134
Drug: Intracoronary (IC)
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary (IC) abciximab administration
Study: 20817283
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous (IV) abciximab administration
Study: 19363853
Drug: NB‐UVB +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB‐UVB + LCD therapy
Study: 15238567
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (16 mg once daily)
Study: 8023667
Drug: Preoperative infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative infiltration of the surgical area with bupivacaine 0.25%, 40 ml (group I)
Study: 2641954
Drug: 0.2% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% NaF solution
Study: 31486196
Drug: Plantain syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantain syrup and placebo capsule
Study: 31486196
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid capsule and placebo syrup
Study: 28483402
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg daily for 7 days, 200 mg on the first day)
Study: 26272281
Drug: S0597 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S0597 at 200 μg/d
Study: 26272281
Drug: S0597 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S0597 at 400 μg/d
Study: 16434506
Drug: SRL‐ST (Sirolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL‐ST (Sirolimus therapy after CsA withdrawal)
Study: 2073671
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg nightly (n = 17)
Study: 2073671
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg twice daily (n = 8)
Study: 2073671
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg nightly (n = 23)
Study: 2073671
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg b.i.d. (n = 19)
Study: 6333649
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methylprednisolone sodium succinate (30 mg/kg q6h X2, then 250 mg q6h X6, then tapering over 8 days)
Study: 6333649
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methylprednisolone (1.5 mg/kg q6h X2, then 25 mg q6h X6, then tapering over 8 days)
Study: 6333649
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methylprednisolone sodium succinate
Study: 6333649
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methylprednisolone and placebo
Study: 28840969
Drug: Intraprostatic botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraprostatic botulinum toxin type A injection (200-300 UI in 6-8 mL saline)
Study: 17644330
Drug: Radiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and tamoxifen 30 mg/day for one year (RT+tam)
Study: 16096179
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% applied twice daily (BID)
Study: 1387246
Drug: Ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15 mg/kg
Study: 20655106
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (5 parts per million)
Study: 30518130
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplement (0.4 g protein/kg/day)
Study: 11998383
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with perfluothane (Control)
Study: 7985708
Drug: Dietary fiber
Normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fiber (20 g/day) administered twice a day for 36 weeks
Study: 30106535
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg codeine + 500 mg paracetamol (CP)
Study: 30106535
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen (IB)
Study: 30106535
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg placebo (PL)